Physician profile
Michael A Moriarty
NPI 1487072112
$8,359.23
in general payments reported to CMS, 2019-2025
21 companies · $4,446 in 2025
The $4,446 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $1,168 · 2021: $280 · 2022: $1,453 · 2023: $290 · 2024: $599 · 2025: $4,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $1,855 · Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $1,854.76 |
| Food and Beverage | $480.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,981.70 | 2024-2025 | |
| Valencia Technologies Corporation | $1,135.96 | 2022 | |
| Neotract INC. | $1,103.41 | 2020 | |
| Boston Scientific Corporation | $265.79 | 2019-2022 | |
| Teleflex LLC | $160.81 | 2021 | |
| 180 Medical, INC. | $128.36 | 2022-2025 | Cure Catheter, Gentlecath Glide |
| Janssen Biotech, INC. | $111.23 | 2019-2023 | Erleada |
| Axonics, INC. | $83.40 | 2021-2023 | Bulkamid, Axonics |
| Pfizer INC. | $76.35 | 2019-2023 | |
| Abbvie INC. | $47.36 | 2023-2024 | |
| Medtronic, INC. | $44.21 | 2023 | Interstim |
| Astellas Pharma US INC | $41.09 | 2022-2023 | Xtandi |
| Endo Pharmaceuticals INC. | $28.46 | 2022-2023 | Aveed, Xiaflex, Edex |
| Myriad Genetic Laboratories, INC. | $27.45 | 2023 | Precisetumor |
| Janssen Scientific Affairs, LLC | $23.58 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $19.49 | 2022 | |
| Coloplast Corp | $19.22 | 2020 | |
| Merck Sharp & Dohme LLC | $17.62 | 2023 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $17.12 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $13.52 | 2025 | |
| Olympus America INC. | $13.10 | 2023 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moriarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.